Pyramax

DRUG6 trials

Sponsors

Medicines for Malaria Venture, University of Kinshasa, Shin Poong Pharmaceutical Co. Ltd., European and Developping Countries Clinical Trials partnership EDCTP, Merck Healthcare KGaA

Conditions

COVID-19MalariaMalaria in Pregnancy

Phase 1

Pyronaridine Artesunate-Ritonavir Drug-drug Interaction Study

CompletedNCT01156389

Medicines for Malaria VentureMalaria

Start: 2010-07-31End: 2010-09-30Updated: 2023-02-03

Phase 2

Pilot Clinical Trial to Explore Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients

CompletedNCT05633420

Shin Poong Pharmaceutical Co. Ltd.COVID-19

Start: 2022-07-24End: 2022-11-20Updated: 2022-12-02

Active, not recruitingPACTR202302515279954

Merck Healthcare KGaAMalaria

Start: 2023-02-20Target: 137Updated: 2026-01-27

Phase 3

Comparison of ISTp- PYRAMAX-US-RDT to IPTp-SP to Prevent Malaria in Pregnant Women in DRC (ULTRAPYRAPREG)

CompletedNCT04783051

University of KinshasaMalaria in Pregnancy

Start: 2021-05-06End: 2022-06-22Updated: 2022-11-04

The Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients (Phase3)

CompletedNCT05084911

Shin Poong Pharmaceutical Co. Ltd.COVID-19

Start: 2021-10-18End: 2023-03-24Updated: 2023-06-18

Phase 4

In vivo study to monitor the sensitivity of Plasmodium falciparum and other species to Pyronaridineartesunate and Artemether-lumefantrine in Niger.

Active, not recruitingPACTR202105706263530

European and Developping Countries Clinical Trials partnership EDCTPMalaria

Start: 2019-11-14Target: 240Updated: 2026-01-27

Related Papers

Intermittent screening using ultra-sensitive malaria rapid diagnostic test and treatment with pyronaridine-artesunate compared to standard preventive treatment with sulfadoxine-pyrimethamine for malaria prevention in pregnant women in Kinshasa, DRC

Malaria Journal2025-02-213 citations

Comparison of intermittent screening (using ultra-sensitive malaria rapid diagnostic test) and treatment (using a newly registered antimalarial pyronaridine-artesunate-PYRAMAX®) to standard intermittent preventive treatment with sulfadoxine-pyrimethamine for the prevention of malaria in pregnant women living in endemic areas: ULTRAPYRAPREG.

2022-11-288 citations